Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 8 (August)

1. The leader sequence triggers and enhances several functions of clusterin and is instrumental in the progression of human prostate cancer in vivo and in vitro.
   BJU Int, 98(2): 452-60. [Abstract] [Full-text]
2. Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score.
   BJU Int, 98(2): 445-51. [Abstract] [Full-text]
3. Concurrent radical retropubic prostatectomy and Lichtenstein inguinal hernia repair through a single modified Pfannenstiel incision: a 3-year experience.
   BJU Int, 98(2): 341-4. [Abstract] [Full-text]
4. Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma.
   BJU Int, 98(2): 335-40. [Abstract] [Full-text]
5. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.
   BJU Int, 98(2): 329-34. [Abstract] [Full-text]
6. Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer.
   BJU Int, 98(2): 324-8. [Abstract] [Full-text]
7. Suburethral sling at the time of radical prostatectomy in patients at high risk of postoperative incontinence.
   BJU Int, 98(2): 308-13. [Abstract] [Full-text]
8. Radical prostatectomy in patients infected with human immunodeficiency virus.
   BJU Int, 98(2): 303-7. [Abstract] [Full-text]
9. Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells.
   Biochem Biophys Res Commun, 347(4): 1158-65. [Abstract] [Full-text]
10. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing.
    Am J Epidemiol, 164(4): 376-84. [Abstract] [Full-text]
11. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.
    Am J Clin Oncol, 29(4): 395-8. [Abstract] [Full-text]
12. A phase II study of higher dose docetaxel in androgen-independent prostate cancer.
    Am J Clin Oncol, 29(4): 389-94. [Abstract] [Full-text]
13. Metastatic ductal adenocarcinoma of the prostate: cytologic features and clinical findings.
    Am J Clin Pathol, 126(2): 302-9. [Abstract] [Full-text]
14. Preparation of a single prostate needle biopsy specimen for histological diagnosis and RNA analysis.
    J Urol, 176(3): 1204-7. [Abstract] [Full-text]
15. Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy.
    J Urol, 176(3): 1118-21. [Abstract] [Full-text]
16. Is race a positive predictor of cancer on repeat prostate biopsy?
    J Urol, 176(3): 1114-7. [Abstract] [Full-text]
17. Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men.
    J Urol, 176(3): 1108-13. [Abstract] [Full-text]
18. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study.
    J Urol, 176(3): 1012-6. [Abstract] [Full-text]
19. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading.
    J Urol, 176(3): 991-5. [Abstract] [Full-text]
20. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
    J Urol, 176(3): 985-90. [Abstract] [Full-text]
21. Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome.
    J Urol, 176(3): 979-84; discussion 984. [Abstract] [Full-text]
22. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    J Urol, 176(3): 972-8; discussion 978. [Abstract] [Full-text]
23. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial.
    J Urol, 176(3): 965-70; discussion 970-1. [Abstract] [Full-text]
24. Prostate saturation biopsy in the reevaluation of microfocal prostate cancer.
    J Urol, 176(3): 961-3; discussion 963-4. [Abstract] [Full-text]
25. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy.
    J Urol, 176(3): 954-60; discussion 960. [Abstract] [Full-text]
26. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
    J Urol, 176(3): 868-74. [Abstract] [Full-text]
27. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis.
    J Clin Oncol, 24(23): 3763-70. [Abstract] [Full-text]
28. TGF-beta in cancer and as a therapeutic target.
    Biochem Pharmacol, 72(5): 523-9. [Abstract] [Full-text]
29. Isolated recurrence of ductal prostate cancer to anterior urethra.
    Urology, 68(2): 428.e13-5. [Abstract] [Full-text]
30. Management of a malignant urinary fistula by ureteral embolization with coils.
    Urology, 68(2): 427.e1-3. [Abstract] [Full-text]
31. Transperitoneal versus extraperitoneal laparoscopic radical prostatectomy: experience of a single center.
    Urology, 68(2): 376-80. [Abstract] [Full-text]
32. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer.
    Urology, 68(2): 371-5. [Abstract] [Full-text]
33. Radical prostatectomy for high-grade prostate cancer.
    Urology, 68(2): 367-70. [Abstract] [Full-text]
34. Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features.
    Urology, 68(2): 362-6. [Abstract] [Full-text]
35. Neuro-fuzzy system for prostate cancer diagnosis.
    Urology, 68(2): 357-61. [Abstract] [Full-text]
36. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
    Urology, 68(2): 342-7. [Abstract] [Full-text]
37. Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer.
    Int J Radiat Oncol Biol Phys, 66(1): 38-47. [Abstract] [Full-text]
38. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage.
    Int J Radiat Oncol Biol Phys, 66(1): 3-10. [Abstract] [Full-text]
39. Continuing evidence for poorer treatment outcomes for single male patients: retreatment data from RTOG 97-14.
    Int J Radiat Oncol Biol Phys, 66(1): 229-33. [Abstract] [Full-text]
40. Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10.
    Int J Radiat Oncol Biol Phys, 66(1): 25-30. [Abstract] [Full-text]
41. First-year PSA kinetics and minima after prostate cancer radiotherapy are predictive of overall survival.
    Int J Radiat Oncol Biol Phys, 66(1): 20-4. [Abstract] [Full-text]
42. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.
    Clin Immunol, 120(3): 297-309. [Abstract] [Full-text]
43. Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 66(1): 31-7. [Abstract] [Full-text]
44. Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling.
    Int J Radiat Oncol Biol Phys, 66(1): 11-9. [Abstract] [Full-text]
45. Temporal relationship between prostate brachytherapy and the diagnosis of colorectal cancer.
    Int J Radiat Oncol Biol Phys, 66(1): 48-55. [Abstract] [Full-text]
46. Cell death induced by MPPa-PDT in prostate carcinoma in vitro and in vivo.
    Biochem Biophys Res Commun, 348(2): 413-20. [Abstract] [Full-text]
47. Differential proteomic alterations between localised and metastatic prostate cancer.
    Br J Cancer, 95(4): 425-30. [Abstract] [Full-text]
48. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
    Br J Cancer, 95(4): 457-62. [Abstract] [Full-text]
49. Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells.
    Br J Cancer, 95(4): 485-95. [Abstract] [Full-text]
50. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
    J Natl Cancer Inst, 98(16): 1134-41. [Abstract] [Full-text]
51. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
    J Natl Cancer Inst, 98(16): 1128-33. [Abstract] [Full-text]
52. The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/prokineticin 1 and 2 and receptor expression in human prostate: Up-regulation of EG-VEGF/prokineticin 1 with malignancy.
    Endocrinology, 147(9): 4245-51. [Abstract] [Full-text]
53. Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer.
    Mol Cell Biol, 26(17): 6502-10. [Abstract] [Full-text]
54. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
    J Clin Oncol, 24(24): 3984-90. [Abstract] [Full-text]
55. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
    J Clin Oncol, 24(24): 3979-83. [Abstract] [Full-text]
56. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.
    J Clin Oncol, 24(24): 3973-8. [Abstract] [Full-text]
57. Genetic aberrations in prostate cancer by microarray analysis.
    Int J Cancer, 119(6): 1322-9. [Abstract] [Full-text]
58. Alcohol consumption and prostate cancer risk: results from the Melbourne collaborative cohort study.
    Int J Cancer, 119(6): 1501-4. [Abstract] [Full-text]
59. Immunohistochemical study of cell proliferation, Bcl-2, p53, and caspase-3 expression on preneoplastic changes induced by cadmium and zinc chloride in the ventral rat prostate.
    J Histochem Cytochem, 54(9): 981-90. [Abstract] [Full-text]
60. Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer.
    Bioorg Med Chem, 14(19): 6525-38. [Abstract] [Full-text]
61. The synthesis of L-carvone and limonene derivatives with increased antiproliferative effect and activation of ERK pathway in prostate cancer cells.
    Bioorg Med Chem, 14(19): 6539-47. [Abstract] [Full-text]
62. Genistein inhibits matrix metalloproteinase type 2 activation and prostate cancer cell invasion by blocking the transforming growth factor beta-mediated activation of mitogen-activated protein kinase-activated protein kinase 2-27-kDa heat shock protein pathway.
    Mol Pharmacol, 70(3): 869-77. [Abstract] [Full-text]
63. The regulation of adiponectin receptors in human prostate cancer cell lines.
    Biochem Biophys Res Commun, 348(3): 832-8. [Abstract] [Full-text]
64. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    BJU Int, 98(3): 580-5. [Abstract] [Full-text]
65. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up.
    BJU Int, 98(3): 573-9. [Abstract] [Full-text]
66. Importance of peripheral biopsies in maximising the detection of early prostate cancer in repeat 12-core biopsy protocols.
    BJU Int, 98(3): 559-62. [Abstract] [Full-text]
67. Histological changes in prostate biopsies after salvage cryotherapy: effect of chronology and the method of biopsy.
    BJU Int, 98(3): 554-8. [Abstract] [Full-text]
68. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    BJU Int, 98(3): 549-53. [Abstract] [Full-text]
69. Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer.
    BJU Int, 98(3): 544-8. [Abstract] [Full-text]
70. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy.
    BJU Int, 98(3): 540-3. [Abstract] [Full-text]
71. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?
    BJU Int, 98(3): 537-9. [Abstract] [Full-text]
72. Anaesthetic considerations for endoscopic extraperitoneal and laparoscopic transperitoneal radical prostatectomy.
    BJU Int, 98(3): 508-13. [Abstract] [Full-text]
73. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    BJU Int, 98(3): 563-72. [Abstract] [Full-text]
74. Combined MRI and MR spectroscopy of the prostate before radical prostatectomy.
    AJR Am J Roentgenol, 187(3): 724-30. [Abstract] [Full-text]
75. Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells.
    Int J Cancer, 119(7): 1586-98. [Abstract] [Full-text]
76. Risk factors for prostate cancer: A national case-control study.
    Int J Cancer, 119(7): 1690-4. [Abstract] [Full-text]
77. Identification of an inhibitory cis-element in the promoter region of human homeobox gene NKX3.1.
    Prostate, 66(12): 1339-46. [Abstract] [Full-text]
78. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
    Prostate, 66(12): 1329-38. [Abstract] [Full-text]
79. Rising prostate cancer rates in South Korea.
    Prostate, 66(12): 1285-91. [Abstract] [Full-text]
80. MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment.
    Prostate, 66(12): 1275-84. [Abstract] [Full-text]
81. Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability.
    Prostate, 66(12): 1292-301. [Abstract] [Full-text]
82. Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heatshock protein 60 as a marker for prostate malignancy.
    Prostate, 66(12): 1235-44. [Abstract] [Full-text]
83. An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines.
    Prostate, 66(12): 1245-56. [Abstract] [Full-text]
84. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion.
    Prostate, 66(12): 1311-8. [Abstract] [Full-text]
85. Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: an autopsy study.
    Prostate, 66(12): 1319-28. [Abstract] [Full-text]
86. Generation of interleukin-17 receptor-like protein (IL-17RL) in prostate by alternative splicing of RNA.
    Prostate, 66(12): 1268-74. [Abstract] [Full-text]
87. Mahanine inhibits growth and induces apoptosis in prostate cancer cells through the deactivation of Akt and activation of caspases.
    Prostate, 66(12): 1257-65. [Abstract] [Full-text]
88. A novel role for 3, 4-dichloropropionanilide (DCPA) in the inhibition of prostate cancer cell migration, proliferation, and hypoxia-inducible factor 1alpha expression.
    BMC Cancer, 6: 204. [Abstract] [Full-text]
89. Loss of proline-rich tyrosine kinase 2 function induces spreading and motility of epithelial prostate cells.
    J Cell Physiol, 209(1): 74-80. [Abstract] [Full-text]
90. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Cancer, 107(5): 1093-100. [Abstract] [Full-text]
91. Cancer incidence after localized therapy for prostate cancer.
    Cancer, 107(5): 991-8. [Abstract] [Full-text]
92. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
    Cancer, 107(5): 975-81. [Abstract] [Full-text]
93. BRAF and KRAS mutations in prostatic adenocarcinoma.
    Int J Cancer, 119(8): 1858-62. [Abstract] [Full-text]
94. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy.
    Int J Cancer, 119(8): 1902-7. [Abstract] [Full-text]
95. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
    J Clin Oncol, 24(25): 4190-5. [Abstract] [Full-text]
96. Risk of cardiovascular mortality in prostate cancer patients in the Rotterdam randomized screening trial.
    J Clin Oncol, 24(25): 4184-9. [Abstract] [Full-text]
97. Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial.
    J Clin Oncol, 24(25): 4158-62. [Abstract] [Full-text]
98. ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression.
    Oncogene, 25(39): 5462-6. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.